Trial Profile
Non-Invasive Measures of Distal Lung Disease in Asthmatics Before and After Treatment With Omalizumab.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary) ; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- 08 Mar 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 May 2010 Planned end date changed from 1 Nov 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.
- 20 Feb 2009 Actual initiation date (Feb 2009) added as reported by ClinicalTrials.gov.